{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:36:55Z","timestamp":1764085015658},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.7759\/cureus.33161","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T10:28:20Z","timestamp":1672482500000},"source":"Crossref","is-referenced-by-count":2,"title":["Postop Complication With Euglycemic Diabetic Ketoacidosis in a Patient Receiving Empagliflozin"],"prefix":"10.7759","author":[{"given":"Jo\u00e3o","family":"Fustiga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"D\u00e2maso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana A","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation. 2021, 143:337-49. 10.1161\/CIRCULATIONAHA.120.051824","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-016-0789-4","article-title":"SGLT2 Inhibitors: benefit\/risk balance","volume":"16","author":"Scheen AJ","year":"2016","unstructured":"Scheen AJ. SGLT2 Inhibitors: benefit\/risk balance. Curr Diab Rep. 2016, 16:92. 10.1007\/s11892-016-0789-4","journal-title":"Curr Diab Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2021.02.015","article-title":"Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management","volume":"44","author":"Long B","year":"2021","unstructured":"Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med. 2021, 44:157-60. 10.1016\/j.ajem.2021.02.015","journal-title":"Am J Emerg Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2021.266","article-title":"Euglycemic diabetic ketoacidosis (EDKA) in a patient receiving dapagliflozin","volume":"17","author":"Sethi SM","year":"2021","unstructured":"Sethi SM, Vohra M, Ali SA. Euglycemic diabetic ketoacidosis (EDKA) in a patient receiving dapagliflozin. Acta Endocrinol (Buchar). 2021, 17:266-9. 10.4183\/aeb.2021.266","journal-title":"Acta Endocrinol (Buchar)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7074868","article-title":"Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis","volume":"2018","author":"Yu X","year":"2018","unstructured":"Yu X, Zhang S, Zhang L. Newer perspectives of mechanisms for euglycemic diabetic ketoacidosis. Int J Endocrinol. 2018, 2018:7074868. 10.1155\/2018\/7074868","journal-title":"Int J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/BF00569937","article-title":"Euglycaemic diabetic ketoacidosis: does it exist?","volume":"30","author":"Jenkins D","year":"1993","unstructured":"Jenkins D, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic ketoacidosis: does it exist?. Acta Diabetol. 1993, 30:251-3. 10.1007\/BF00569937","journal-title":"Acta Diabetol"},{"key":"ref7","article-title":"Euglycemic Diabetic Ketoacidosis","author":"Plewa MC","year":"2022","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/869186","article-title":"Breath ketone testing: a new biomarker for diagnosis and therapeutic monitoring of diabetic ketosis","volume":"2014","author":"Qiao Y","year":"2014","unstructured":"Qiao Y, Gao Z, Liu Y, et al.. Breath ketone testing: a new biomarker for diagnosis and therapeutic monitoring of diabetic ketosis. Biomed Res Int. 2014, 2014:869186. 10.1155\/2014\/869186","journal-title":"Biomed Res Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau JE","year":"2017","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017, 33:e2924. 10.1002\/dmrr.2924","journal-title":"Diabetes Metab Res Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis","volume":"12","author":"Nasa P","year":"2021","unstructured":"Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes. 2021, 12:514-23. 10.4239\/wjd.v12.i5.514","journal-title":"World J Diabetes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-22-0290","article-title":"Diabetes mellitus-induced lower urinary tract symptoms and hepatic steatosis in an older male [IN PRESS]","volume":"2022","author":"Opara NU","year":"2022","unstructured":"Opara NU. Diabetes mellitus-induced lower urinary tract symptoms and hepatic steatosis in an older male [IN PRESS]. Endocrinol Diabetes Metab Case Rep. 2022, 2022:10.1530\/EDM-22-0290","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort","volume":"11","author":"Ata F","year":"2021","unstructured":"Ata F, Yousaf Z, Khan AA, et al.. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021, 11:10293. 10.1038\/s41598-021-89752-w","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/128017-postop-complication-with-euglycemic-diabetic-ketoacidosis-in-a-patient-receiving-empagliflozin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:53Z","timestamp":1707508133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/128017-postop-complication-with-euglycemic-diabetic-ketoacidosis-in-a-patient-receiving-empagliflozin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.33161","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,31]]}}}